Menu
Search
|

Menu

Close
X

Alimera Sciences Inc ALIM.OQ (NASDAQ Stock Exchange Global Market)

1.02 USD
+0.00 (+0.00%)
As of Nov 13
chart
Previous Close 1.02
Open 1.01
Volume 16,291
3m Avg Volume 28,389
Today’s High 1.04
Today’s Low 0.99
52 Week High 1.37
52 Week Low 0.74
Shares Outstanding (mil) 70.08
Market Capitalization (mil) 70.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
21
FY17
36
FY16
34
FY15
22
EPS (USD)
FY18
-0.167
FY17
-0.328
FY16
-0.656
FY15
-0.689
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
1.77
15.43
Price to Book (MRQ)
vs sector
--
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
686.35
14.84
LT Debt to Equity (MRQ)
vs sector
682.54
11.13
Return on Investment (TTM)
vs sector
-47.37
12.77
Return on Equity (TTM)
vs sector
--
14.47

EXECUTIVE LEADERSHIP

Richard Eiswirth
President, Chief Financial Officer, Since 2016
Salary: $394,000.00
Bonus: $7,880.00
Rich Cockrell
President, Since 2015
Salary: --
Bonus: --
C. Daniel Myers
Chief Executive Officer, Since 2016
Salary: $504,000.00
Bonus: $13,860.00
Kenneth Green
Senior Vice President, Chief Scientific Officer, Since 2007
Salary: $350,000.00
Bonus: $7,000.00
David Holland
Senior Vice President - Sales and Marketing, Since 2010
Salary: $344,000.00
Bonus: $6,880.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

6120 Windward Pkwy Ste 290
ALPHARETTA   GA   30005-8897

Phone: +1678.9905740

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

SPONSORED STORIES